RP is a genetic retinal disease and retinal degenerative, which causes the rod cells of the retina to lose their function. It causes blindness in approximately 40 per 100,000 people by the age of 50. It is a genetically heterogeneous disease with different allelic patterns. It is estimated that more than 100 genes of the retinal photoreceptor are implicated in the development of RP. It becomes progressively more severe as the number of mutated photoreceptor genes increases.
Signs of RP include blurred vision, night blindness, reduced visual field, poor dark adaptation, inability to detect color contrasts and/or glare, and changes in appearance from birth or around age 6. If the child is able to walk, signs of progressive, fluctuating deafness can develop, and if hospitalized the lack of communication can become evident.
While there is no conclusive treatment for retinitis pigmentosa, eye lubrication and a good diet are critical for the maintenance of vision in patients with retinitis pigmentosa. Eye surgery is another option that can be taken into account, but the decision depends heavily on individual patient wishes for a less invasive treatment option.
The number of patients with any form of RPE was 2% of the total population. Only 2 patients had both optic nerve atrophy and RP. On average, an RPE patient lived 3 to 5 years more than the general population.
The cause of RP is only unknown in a considerable part of the patients. Most patients are not referred to a specialist in a timely manner, which leads to an inadequate evaluation of other medical conditions that are relevant to the genesis or course of RP.
This pilot study suggests that most patients can be cured with a retinal transplant. More research is needed to further refine the ideal candidate and the timing of the transplant.
Even we believe we have found cure for RP, we wouldn't be satisfied until a patient who suffers from RP has a fully functional retina and has the ability to see. The only thing we can do now is to do our best to prevent the disease, treat patients as soon as we can, and continue this topic for a long time, especially as our population grows. We hope that we'll learn more.
Most people can live relatively normal lives, even with severe RP. However, the disease can have many serious consequences especially in the later stages. The impact of RP varies greatly with age and severity, but can have lifelong consequences on quality of life and vision. Further research is needed to develop a more comprehensive and accurate RP severity rating system in order to assess the true severity of RP and develop interventions for the management of RP. It is important to look after the eye to prevent blindness.
The study has shown that retinitis pigmentosa shows increased occurrence of consanguineous marriages. In case of sporadic inheritance there is increased prevalence of recessive forms. Further studies have demonstrated that this hereditary and autosomal dominant inheritance can be divided into two parts named as dominant or recessive. The hereditary form with autosomal dominance has more severe symptoms and often progresses to bilateral retinal detachment.
The 4d-125 IVT injection results in a significant decrease of macular swelling and a significant increase of central vision, without altering visual acuity. The patient's subjective self-assessment is that IVT injection does not substantially affect daily life. The IVT injection is the most potent topical drug for controlling ocular hypertension and retinopathy in patients with X-linked RP.
The 4d-125 ivt protocol in conjunction with the use of ophthalmic topical treatment of the eye is associated with a higher rate of treatment completion and a lower number of patients who develop complications as compared with the traditional IVT protocol.
4d-125 ivt is often used as a component of a 4 treatment regimen, with the primary purpose of providing higher dosages of photoreceptor toxic drugs when compared with a 2 treatment regimen.